 |
|
|
| |
Once-Daily Sofosbuvir/Ledipasvir Fixed-Dose Combination With or Without Ribavirin Resulted in 97% Sustained Virologic Response in Patients With HCV Genotype 1, Including Patients With Cirrhosis: The LONESTAR Trial
|
| |
| |
Reported by Jules Levin
APASL 2014, Brisbane, Australia
Eric Lawitz1, Fred F. Poordad1, Robert H. Hyland2, Xiao Ding2, Hongmei Mo2,
Phillip S. Pang2, William T. Symonds2, Fernando E. Membreno1
1Texas Liver Institute and University of Texas Health Science Center, San Antonio, USA; 2Gilead Sciences, Inc., Foster City, California, USA
|
| |
|
|
|
|
|
